DAREDare Bioscience, Inc.

Nasdaq darebioscience.com


$ 0.39 $ 0.00 (-0.89 %)    

Thursday, 16-May-2024 12:00:21 EDT
QQQ $ 453.97 $ 0.50 (0.11 %)
DIA $ 400.52 $ 0.88 (0.22 %)
SPY $ 530.68 $ 0.75 (0.14 %)
TLT $ 92.13 $ -0.26 (-0.28 %)
GLD $ 220.41 $ 0.40 (0.18 %)
$ 0.36
$ 0.39
$ 0.00 x 0
$ 0.39 x 100
$ 0.39 - $ 0.39
$ 0.27 - $ 1.06
2,186,456
na
36.19M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 04-01-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-28-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-02-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-16-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-06-2015 03-31-2015 10-Q
38 03-19-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-dare-bioscience-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.

 brookline-capital-upgrades-dare-bioscience-to-buy-announces-3-price-target

Brookline Capital analyst Kemp Dolliver upgrades Dare Bioscience (NASDAQ:DARE) from Hold to Buy and announces $3 price target.

 dare-bioscience-q1-eps-007-misses-006-estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0...

 dare-bioscience-files-for-common-stock-offering-of-up-to-181m

-SEC Filing

 dar-bioscience-selected-as-a-member-of-arpa-h-investor-catalyst-hub-spoke-network

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it was selected as a spoke for ...

 hc-wainwright--co-reiterates-buy-on-dare-bioscience-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.

Core News & Articles

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...

 brookline-capital-downgrades-dare-bioscience-to-hold

Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.

 dar-bioscience-announces-publication-in-contraception-of-efficacy-and-safety-findings-from-a-pre-pivotal-postcoital-test-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive e...

 hc-wainwright--co-reiterates-buy-on-dare-bioscience-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.

 dare-bioscience-q4-eps-006-beats-010-estimate-sales-181m-beat-179m-estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION